Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Medicine|August 26, 2023
Evaluation of Retinal Blood Flow in Patients with Monoclonal Gammopathy Using OCT AngiographyCecilia Czakó, Dóra Gerencsér, Kitti Kormányos, et al.
Orvosi Hetilap|November 12, 2023
[How did the survival of acute myeloid leukemia change over the last ten years in our unit?]Lilla Gaál, Eszter Ruff, Ádám Wiedemann, et al.
Nature Communications|May 6, 2021
Regression plane concept for analysing continuous cellular processes with machine learningAbel Szkalisity, Filippo Piccinini, Attila Beleon, et al.
Journal of Clinical Medicine|January 10, 2026
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World AnalysisHermina Sánta, Laura Regáli, László Váróczy, et al.
International Journal of Hematology|August 9, 2019
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patientsSzilvia Lovas, Gergely Varga, Péter Farkas, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Pathology Oncology Research : POR|July 14, 2021
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian CentersGergely Varga, András Dávid Tóth, Virág Réka Szita, et al.
Cancers|September 9, 2023
Outcome of Second Primary Malignancies Developing in Multiple Myeloma PatientsIrit Avivi, David H Vesole, Julio Davila-Valls, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Pageof 5